Anti CEA CAR T cell therapy - Chongqing Precision Biotech
Latest Information Update: 13 Jul 2024
At a glance
- Originator Chongqing Precision Biotech Co., Ltd
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 06 Nov 2023 Chongqing Precision Biotech initiates a phase I trial (Late-stage disease, Recurrent, Metastatic disease, Second line therapy or greater) in China (IV, Intraperitoneal) (NCT06126406)
- 25 Aug 2023 Chongqing Precision Biotech initiates a phase-I trial in Solid tumours (Late-stage disease, Recurrent, Metastatic disease, Second line therapy or greater) in China (IV; Intraperitoneal) (NCT06010862)